Conjugated antibodies and bispecific antibodies in lung cancer: a new hope?

New treatment strategies have been developed in the treatment landscape of patients with advanced lung cancer. These agents include antibody drug conjugates, bi-specific antibodies, and a subtype of bi-specific agent also called the bi-specific T-cell engagers or BiTe. All these drugs have reported promising clinical activity at the time of progression in patients previously treated either with chemotherapy and immunotherapy, but also after failure of personalized treatment approaches and chemotherapy in patients with some oncogenic addicted tumors. In this review, we summarize the clinical data of these treatments and potential challenges with this approach in daily practice.